5 results on '"Riverol, Mario"'
Search Results
2. Awareness of Diagnosis in Persons with Early-Stage Alzheimer's Disease: An Observational Study in Spain
- Author
-
Roche, Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), European Commission, European Federation of Pharmaceutical Industries and Associations, Instituto de Salud Carlos III, Grifols, Fundación la Caixa, Villarejo-Galende, Alberto, García-Arcelay, Elena, Piñol-Ripoll, Gerard, Olmo-Rodríguez, Antonio del, Viñuela, Félix, Boada, Mercè, Franco-Macías, Emilio, Ibáñez de la Peña, Almudena, Riverol, Mario, Puig-Pijoan, Albert, Abizanda-Soler, Pedro, Arroyo, Rafael, Baquero, Miquel, Feria-Vilar, Inmaculada, Balasa, Mircea, Berbel, Ángel, Rodríguez-Rodríguez, Eloy, Vieira-Campos, Alba, García-Ribas, Guillermo, Rodrigo-Herrero, Silvia, Lleó, Alberto, Maurino, Jorge, Roche, Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), European Commission, European Federation of Pharmaceutical Industries and Associations, Instituto de Salud Carlos III, Grifols, Fundación la Caixa, Villarejo-Galende, Alberto, García-Arcelay, Elena, Piñol-Ripoll, Gerard, Olmo-Rodríguez, Antonio del, Viñuela, Félix, Boada, Mercè, Franco-Macías, Emilio, Ibáñez de la Peña, Almudena, Riverol, Mario, Puig-Pijoan, Albert, Abizanda-Soler, Pedro, Arroyo, Rafael, Baquero, Miquel, Feria-Vilar, Inmaculada, Balasa, Mircea, Berbel, Ángel, Rodríguez-Rodríguez, Eloy, Vieira-Campos, Alba, García-Ribas, Guillermo, Rodrigo-Herrero, Silvia, Lleó, Alberto, and Maurino, Jorge
- Abstract
[Introduction] Limited information is available on people’s experiences of living with Alzheimer’s disease (AD) at earlier stages. This study assessed awareness of diagnosis among people with early-stage AD and its impact on different person-centered outcome measures., [Methods] We conducted an observational, cross-sectional study in 21 memory clinics in Spain. Persons aged 50–90 years, diagnosed with prodromal or mild AD (NIA/AA criteria), a Mini Mental State Examination (MMSE) score ≥ 22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5 or 1.0 were recruited. The Representations and Adjustment to Dementia Index (RADIX) was used to assess participants’ beliefs about their condition and its consequences., [Results] A total of 149 persons with early-stage AD were studied. Mean (SD) age was 72.3 (7.0) years and 50.3% were female. Mean duration of AD was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1) and 87.2% had a CDR-GS score of 0.5. Most participants (n = 84, 57.5%) used a descriptive term related to specific AD symptoms (e.g., memory difficulties) when asked what they called their condition. Participants aware of their diagnosis using the term AD (n = 66, 45.2%) were younger, had more depressive symptoms, and poorer life satisfaction and quality of life compared to those without awareness of their specific diagnosis. Practical and emotional consequences RADIX scores showed a significant negative correlation with Quality of Life in Alzheimer’s Disease score (rho = − 0.389 and − 0.413, respectively; p < 0.0001). Years of education was the only predictor of awareness of AD diagnosis [OR = 1.04 (95% CI 1.00–1.08); p = 0.029]., [Conclusions] Awareness of diagnosis was a common phenomenon in persons with early-stage AD negatively impacting their quality of life. Understanding illness representations in earlier stages may facilitate implementing optimized care that supports improved quality of life and well-being.
- Published
- 2022
3. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease
- Author
-
Roche, Villarejo-Galende, Alberto, García-Arcelay, Elena, Piñol-Ripoll, Gerard, Olmo-Rodríguez, Antonio del, Viñuela, Félix, Boada, Mercè, Franco-Macías, Emilio, Ibáñez de la Peña, Almudena, Riverol, Mario, Puig-Pijoan, Albert, Abizanda-Soler, Pedro, Arroyo, Rafael, Baquero, Miquel, Feria-Vilar, Inmaculada, Balasa, Mircea, Berbel, Ángel, Rodríguez-Rodríguez, Eloy, Vieira-Campos, Alba, García-Ribas, Guillermo, Rodrigo-Herrero, Silvia, Terrancle, Ángeles, Prefasi, Daniel, Lleó, Alberto, Maurino, Jorge, Roche, Villarejo-Galende, Alberto, García-Arcelay, Elena, Piñol-Ripoll, Gerard, Olmo-Rodríguez, Antonio del, Viñuela, Félix, Boada, Mercè, Franco-Macías, Emilio, Ibáñez de la Peña, Almudena, Riverol, Mario, Puig-Pijoan, Albert, Abizanda-Soler, Pedro, Arroyo, Rafael, Baquero, Miquel, Feria-Vilar, Inmaculada, Balasa, Mircea, Berbel, Ángel, Rodríguez-Rodríguez, Eloy, Vieira-Campos, Alba, García-Ribas, Guillermo, Rodrigo-Herrero, Silvia, Terrancle, Ángeles, Prefasi, Daniel, Lleó, Alberto, and Maurino, Jorge
- Abstract
[Background] There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages., [Objective] The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD., [Methods] A multicenter, non-interventional study was conducted including patients of 50–90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.–1.0. The Quality of Life in Alzheimer ’s Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman’s rank correlations., [Results] A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness., [Conclusion] Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.
- Published
- 2022
4. Grey matter changes on brain MRI in subjective cognitive decline: a systematic review
- Author
-
Arrondo, Pablo, Elía-Zudaire, Oscar, Martí-Andrés, Gloria, Fernández-Seara, María A., Riverol, Mario, Arrondo, Pablo, Elía-Zudaire, Oscar, Martí-Andrés, Gloria, Fernández-Seara, María A., and Riverol, Mario
- Abstract
[Introduction] People with subjective cognitive decline (SCD) report cognitive deterioration. However, their performance in neuropsychological evaluation falls within the normal range. The present study aims to analyse whether structural magnetic resonance imaging (MRI) reveals grey matter changes in the SCD population compared with healthy normal controls (HC)., [Methods] Parallel systematic searches in PubMed and Web of Science databases were conducted, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Quality assessment was completed using the Newcastle-Ottawa Scale (NOS)., [Results] Fifty-one MRI studies were included. Thirty-five studies used a region of interest (ROI) analysis, 15 used a voxel-based morphometry (VBM) analysis and 10 studies used a cortical thickness (CTh) analysis. Ten studies combined both, VBM or CTh analysis with ROI analysis., [Conclusions] Medial temporal structures, like the hippocampus or the entorhinal cortex (EC), seemed to present grey matter reduction in SCD compared with HC, but the samples and results are heterogeneous. Larger sample sizes could help to better determine if these grey matter changes are consistent in SCD subjects.
- Published
- 2022
5. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment:A European Alzheimer's disease consortium survey
- Author
-
Frederiksen, Kristian S., Nielsen, Thomas R., Appollonio, Ildebrando, Andersen, Birgitte Bo, Riverol, Mario, Boada, Mercè, Ceccaldi, Mathieu, Dubois, Bruno, Engelborghs, Sebastiaan, Frölich, Lutz, Hausner, Lucrezia, Gabelle, Audrey, Gabryelewicz, Tomasz, Grimmer, Timo, Hanseeuw, Bernard, Hort, Jakub, Hugon, Jacques, Jelic, Vesna, Koivisto, Anne, Kramberger, Milica G., Lebouvier, Thibaud, Lleó, Alberto, de Mendonça, Alexandre, Nobili, Flavio, Ousset, Pierre Jean, Perneczky, Robert, Olde Rikkert, Marcel, Robinson, David, Rouaud, Olivier, Sánchez, Elisabet, Santana, Isabel, Scarmeas, Nikolaos, Sheardova, Katerina, Sloan, Stephanie, Spiru, Luiza, Stefanova, Elka, Traykov, Latchezar, Yener, Görsev, Waldemar, Gunhild, Frederiksen, Kristian S., Nielsen, Thomas R., Appollonio, Ildebrando, Andersen, Birgitte Bo, Riverol, Mario, Boada, Mercè, Ceccaldi, Mathieu, Dubois, Bruno, Engelborghs, Sebastiaan, Frölich, Lutz, Hausner, Lucrezia, Gabelle, Audrey, Gabryelewicz, Tomasz, Grimmer, Timo, Hanseeuw, Bernard, Hort, Jakub, Hugon, Jacques, Jelic, Vesna, Koivisto, Anne, Kramberger, Milica G., Lebouvier, Thibaud, Lleó, Alberto, de Mendonça, Alexandre, Nobili, Flavio, Ousset, Pierre Jean, Perneczky, Robert, Olde Rikkert, Marcel, Robinson, David, Rouaud, Olivier, Sánchez, Elisabet, Santana, Isabel, Scarmeas, Nikolaos, Sheardova, Katerina, Sloan, Stephanie, Spiru, Luiza, Stefanova, Elka, Traykov, Latchezar, Yener, Görsev, and Waldemar, Gunhild
- Abstract
Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.